IL-12 Gene Therapy IMNN-001 Adds 13-Month OS to Front-Line Chemo in Advanced Ovarian Cancer
- Trial ID
- NCT03393884 on ClinicalTrials.gov
- Cancer type
- Ovarian Cancer
- Published in
- New in Oncology - June 6, 2025
IMNN-001 works by stimulating local production of IL-12, which activates immune cells to attack the cancer. In the randomized phase I/II OVATION-2 trial (NCT03393884), 112 women with stage III/IV epithelial ovarian cancer received standard carboplatin-paclitaxel with or without weekly intraperitoneal IMNN-001 during neoadjuvant and adjuvant cycles; median overall survival rose to 46.0 vs 33.0 months (HR 0.69) and progression-free survival to 14.9 vs 11.9 months (HR 0.79), with no cytokine-release syndrome and only grade 1-2 abdominal symptoms added.
Take home
If phase III confirms these survival gains, IMNN-001 could usher in the first intraperitoneal gene-immunotherapy to meaningfully boost front-line outcomes—especially valuable for HRD-positive patients poised for PARP maintenance (based on subgroup analysis).
Source: Read the original publication
More in ovarian cancer
-
Trial result · Oct 22, 2026 · NCT07213804
Sofetabart mipitecan (FRα-targeted ADC) posts 50.5% ORR and 8.1-mo mPFS in heavily pretreated HGOC—without keratopathy -
New trial · Oct 15, 2026 · NCT07851025
Phase 3 TREVI-OC-02 tests FRα-targeted torvutatug samrotecan plus bevacizumab maintenance in HRD-negative ovarian cancer -
New trial · Oct 15, 2026 · NCT07504588
Phase 2 NRG-GY038 compares sacituzumab govitecan plus bevacizumab with platinum-based treatment after PARP-inhibitor progression -
New trial · Oct 15, 2026 · NCT07776691
Phase 3 REJOICE-Ovarian04 tests CDH6-targeted raludotatug deruxtecan maintenance with or without bevacizumab -
New trial · Oct 8, 2026 · NCT07816666
Phase 3 torvutatug samrotecan FRα (FOLR1) ADC with exatecan (topoisomerase I) payload